Altered Expression of Smad Proteins in T or NK-cell Lymphomas
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Smad proteins mediate cellular signaling through the transforming growth factor-β family (TGF-β s). Smads 2 and 3 transmit signals from TGF-β, and Smad4 is a common mediator, as well. However, little is known concerning the expression patterns of Smads in lymphoid tissue. Materials and Methods: Immunohistochemistry for Smad3 and Smad4 was performed on paraffin-embedded tissue sections collected from 26 T- or NK-cell lymphomas. Results: Nearly all cells in germinal centers were positive for Smad3, and more than 50% of paracortical cells were positive for Smad3 in reactive lymphoid tissue. When Smad4 immunostaining was conducted, nearly all the cells in the germinal centers showed diffuse cytoplasmic staining, and most of them exhibited nuclear positivity, as well. In addition, more than 50% of the cells in the paracortex were positive for Smad4. Furthermore, the Smad3 staining pattern was preserved in all malignant lymphomas, but four of these cases (15%) exhibited decreased expression of Smad4. All lymphoblastic lymphomas showed strong positivity in most of tumor cells, but one unspecified peripheral lymphoma, two nasal NK/T cell lymphomas, and one anaplastic large cell lymphoma were negative for Smad4. Conclusions: These results suggest that TGF-β-specific Smads may be actively involved in signal transduction in lymphoid organs and that Smad-mediated TGF-β signaling pathways are operative in malignant lymphoma. In addition, loss of Smad4 expression might be associated with development of some T-cell lymphomas.
Abstract
Purpose: Smad proteins mediate cellular signaling through the transforming growth factor-β family (TGF-β s). Smads 2 and 3 transmit signals from TGF-β, and Smad4 is a common mediator, as well. However, little is known concerning the expression patterns of Smads in lymphoid tissue. Materials and Methods: Immunohistochemistry for Smad3 and Smad4 was performed on paraffin-embedded tissue sections collected from 26 T- or NK-cell lymphomas. Results: Nearly all cells in germinal centers were positive for Smad3, and more than 50% of paracortical cells were positive for Smad3 in reactive lymphoid tissue. When Smad4 immunostaining was conducted, nearly all the cells in the germinal centers showed diffuse cytoplasmic staining, and most of them exhibited nuclear positivity, as well. In addition, more than 50% of the cells in the paracortex were positive for Smad4. Furthermore, the Smad3 staining pattern was preserved in all malignant lymphomas, but four of these cases (15%) exhibited decreased expression of Smad4. All lymphoblastic lymphomas showed strong positivity in most of tumor cells, but one unspecified peripheral lymphoma, two nasal NK/T cell lymphomas, and one anaplastic large cell lymphoma were negative for Smad4. Conclusions: These results suggest that TGF-β-specific Smads may be actively involved in signal transduction in lymphoid organs and that Smad-mediated TGF-β signaling pathways are operative in malignant lymphoma. In addition, loss of Smad4 expression might be associated with development of some T-cell lymphomas.
참고문헌 (22)
- de Caestecker MP, "The Smad4 activation domain (SAD) is aproline-rich, p300-dependent transcriptional activation domain", J Biol Chem, 275, pp.2115~22 (2000)
- Flanders KC, "Immunohistochemicalexpression of Smads 1-6 in the 15-day gestation mouseembryo: signaling by BMPs and TGF-betas", Dev Dyn, 220, pp.141~54 (2001)
- Larisch-Bloch S., "Selective loss of the transforming growthfactor-beta apoptotic signaling pathway in mutant NRP-154 ratprostatic epithelial cells", Cell Growth Differ, 11, pp.1~10 (2000)
- Patil S., "Smad7 is induced by CD40 and protects WEHI 231B-lymphocytes from transforming growth factor-beta -inducedgrowth inhibition and apoptosis", J Biol Chem, 275, pp.38363~70 (2000)
- Miyazono K., "TGF-beta receptors and signal transduction", IntJ Hematol, 65, pp.97~104 (1997)
- Schiemann WP, "A deletion in the gene for transforming growth factor beta typeI receptor abolishes growth regulation by transforming growthfactor beta in a cutaneous T-cell lymphoma", Blood, 94, pp.2854~61 (1999)
- Kadin ME, "Loss of receptors for transforming growth factorbeta in human T-cell malignancies", Proc Natl Acad Sci USA, 91, pp.6002~6 (1994)
- Knaus PI, "A dominant inhibitory mutant of the typeII transforming growth factor beta receptor in the malignantprogression of a cutaneous T-cell lymphoma", Mol Cell Biol, 16, pp.3480~9 (1996)
- Takaku K., "Intestinal tumorigenesis in compound mutantmice of both Dpc4 (Smad4) and Apc genes", Cell, 92, pp.645~56 (1998)
- Zhu Y., "Smad3 mutantmice develop metastatic colorectal cancer", Cell, 94, pp.703~14 (1998)
- Gorelik L., "Transforming growth factor-beta inT-cell biology. Nat Rev Immunol. 2002;2:46-53.12. Rubtsov YP, Rudensky AY. TGFbeta signalling in control ofT-cell-mediated self-reactivity", Nat Rev Immunol, 7, pp.443~53 (2007)
- Rosendahl A., "Transforming growth factor-beta- and Activin-Smad signalingpathways are activated at distinct maturation stages of thethymopoiesis", Int Immunol, 15, pp.1401~14 (2003)
- Djaborkhel R., "Cyclin A down-regulation in TGFbeta1-arrested follicularlymphoma cells", Exp Cell Res, 261, pp.250~9 (2000)
- Hsu SM, "Abundant expressionof transforming growth factor-beta 1 and -beta 2 by Hodgkin'sReed-Sternberg cells and by reactive T lymphocytes inHodgkin's disease", Hum Pathol, 24, pp.249~55 (1993)
- Go JH, "Decreased expression of TGF-β type 2 receptor inprimary B-cell lymphomas of the stomach", Pathol Res Pract, 198, pp.333~7 (2002)
- Kadin ME, "Immunohistochemical evidence of a role for transforminggrowth factor beta in the pathogenesis of nodular sclerosingHodgkin's disease", Am J Pathol, 136, pp.1209~14 (1990)
- Kim SJ, "Transforming growth factor-beta signalingin normal and malignant hematopoiesis", Leukemia, 17, pp.1731~7 (2003)
- Hu X., "Transforming growth factor: signaltransduction pathways, cell cycle mediation, and effects onhematopoiesis", J Hematother Stem Cell Res, 10, pp.67~74 (2001)
- Yang X, "Targeted disruption of SMAD3 results in impairedmucosal immunity and diminished T cell responsiveness", EMBO J, 18, pp.1280~91 (1999)
- 고재향, "B형 미만성 대세포 림프종에서 Smad 단백의 발현", 대한병리학회지, 38(5), pp.301~305 (2004), 대한병리학회
- Wolfraim LA, "Loss of Smad3 in acute T-cell lymphoblasticleukemia", N Engl J Med, 351, pp.552~9 (2004)
- Chi SG, "Oncogenes by TGF-β1", Cancer Res Treat, 35, pp.12~ (2003)